Child-resistant nasal pump manufacturing capabilities extended at Aptar Pharma’s Congers site

Manufacturer of drug delivery systems for nasal applications, Aptar Pharma, has announced the installation of a new assembly machine for its Child-Resistant and Senior-Friendly Classic Nasal Pumps at the Congers site in North America.

The machine was transferred from the company’s plant in Southern Germany, representing an important step in bringing Aptar Pharma’s manufacturing capacity closer to the target market. Primarily developed for the North American market, the Child-Resistant technology platform matches the US Consumer Product Safety Commission (CPSC) rule, which was issued in 2012, specifying that packaging for any over-the-counter or drug product containing the equivalent of 0.08 mg or more of imidazoline — a formulation widely used in nasal decongestant topical sprays — be child-resistant in design.

Combining child-resistance and senior-friendliness in its design, the packaging solution is a squeeze-and-turn technology. The company reports that major brands of nasal decongestant topical sprays in the US now come with its child-resistant feature.

“We are pleased to welcome the arrival of Aptar Pharma’s Child-Resistant assembly machine to our recently expanded Congers, NY manufacturing site,” said Alex Theodorakis, president of Aptar Pharma North America. “This added manufacturing capacity enables us to offer the production of this key child-resistant/senior friendly feature to our customers domestically. Being closer to our customers continues to be of strategic importance to Aptar Pharma, and this new initiative enables us to continue to support our important North American marketplace and increase our demand reactivity.”